Christopher joined Merck as part of the Inhouse Consulting department in 2014, where he conducted various assignments within the Merck Biopharma Strategy and R&D organizations. In 2015, he joined Merck Healthcare Global Portfolio Management as Associate Director to support the Portfolio Review Process by facilitating non-financial and financial valuation of clinical pipeline assets, with special focus on the Neurology & Immunology franchise. In addition, Christopher has been involved in the 2016 Immunology Franchise Strategy development process and coordinated the cross-sectoral Gene-editing Megatrend initiative in 2016. Having studied both biology and economics at the Universities of Heidelberg & Dublin, Christopher was involved in oncology drug development at the German Cancer Research Center (DKFZ) in Heidelberg where he gained his PhD.